---
title: "中国鹏飞集团附属认购 2800 万港元的华泰理财产品"
description: "智通财经 APP 讯，中国鹏飞集团发布公告，于 2025 年 8 月 6 日，中国重器 (本公司的间接全资附属公司) 透过分销商认购金额为 2800 万港元的华泰理财产品。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/251863950.md"
published_at: "2025-08-06T14:25:03.000Z"
---

# 中国鹏飞集团附属认购 2800 万港元的华泰理财产品

> 智通财经 APP 讯，中国鹏飞集团发布公告，于 2025 年 8 月 6 日，中国重器 (本公司的间接全资附属公司) 透过分销商认购金额为 2800 万港元的华泰理财产品。

智通财经 APP 讯，中国鹏飞集团 (03348) 发布公告，于 2025 年 8 月 6 日，中国重器 (本公司的间接全资附属公司) 透过分销商认购金额为 2800 万港元的华泰理财产品。

### Related Stocks

- [03348.HK - 中国鹏飞集团](https://longbridge.com/zh-CN/quote/03348.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Huatai Securities Keeps Their Buy Rating on China Literature (CHLLF) | In a report released on February 13, from Huatai Securities maintained a Buy rating on China Literature, with a price ta | [Link](https://longbridge.com/zh-CN/news/275996484.md) |
| Beijing Haizhi Technology Announces Final Offer Price | Beijing Haizhi Technology Group Co Ltd:FINAL OFFER PRICE HK$27.06 PER H SHARE UNDER GLOBAL OFFERING | [Link](https://longbridge.com/zh-CN/news/275780031.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-CN/news/276051793.md) |
| 23:43 ETDie innovativen Sicherheits- und hocheffizienten Antriebsstränge von GAC finden weltweite Anerkennung | GAC is gaining global recognition for its innovative and efficient drivetrains amidst the rapidly changing automotive in | [Link](https://longbridge.com/zh-CN/news/275994919.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。